cs.LGFeb 26, 2026

An Explainable Ensemble Framework for Alzheimer's Disease Prediction Using Structured Clinical and Cognitive Data

Authors: Nishan Mitra

Organizations: Computer Science & Engineering (AI&ML), Institute of Engineering & Management, Kolkata, India

Abstract

Early and accurate detection of Alzheimer's disease (AD) remains a major challenge in medical diagnosis due to its subtle onset and progressive nature. This research introduces an explainable ensemble learning Framework designed to classify individuals as Alzheimer's or Non-Alzheimer's using structured clinical, lifestyle, metabolic, and lifestyle features. The workflow incorporates rigorous preprocessing, advanced feature engineering, SMOTE-Tomek hybrid class balancing, and optimized modeling using five ensemble algorithms-Random Forest, XGBoost, LightGBM, CatBoost, and Extra Trees-alongside a deep artificial neural network. Model selection was performed using stratified validation to prevent leakage, and the best-performing model was evaluated on a fully unseen test set. Ensemble methods achieved superior performance over deep learning, with XGBoost, Random Forest, and Soft Voting showing the strongest accuracy, sensitivity, and F1-score profiles. Explainability techniques, including SHAP and feature importance analysis, highlighted MMSE, Functional Assessment Age, and several engineered interaction features as the most influential determinants. The results demonstrate that the proposed framework provides a reliable and transparent approach to Alzheimer's disease prediction, offering strong potential for clinical decision support applications.

Figures & tables

Explore similar work

Apr 14, 2026

Early Detection of Alzheimer's Disease Using Explainable Machine Learning on Clinical Biomarkers: A Multi-Class Classification Study Using the Alzheimer's Disease Neuroimaging Initiative (ADNI) Dataset

Background: Alzheimer's disease (AD) affects over 55 million people worldwide. Accurate, interpretable detection of normal cognition (NC), mild cognitive impairment (MCI), and AD from routine clinical assessments remains a critical unmet need. Methods: An XGBoost classifier was developed for three-class detection using eight clinical features from the Alzheimer's Disease Neuroimaging Initiative (ADNI): MMSE, CDR Global, CDR Sum of Boxes (CDR-SB), MoCA, FAQ, age, sex, and education. Hyperparameters were optimised using Optuna (50 trials); class imbalance was addressed with SMOTE. Performance was evaluated by macro AUC-ROC with 1,000-iteration bootstrap 95% confidence intervals, macro F1, balanced accuracy, and Cohen's kappa. SHAP values provided feature-level explainability. Results: The dataset comprised 1,641 baseline subjects (608 NC, 767 MCI, 266 AD). On five-fold cross-validation, mean macro AUC was 0.983 (SD 0.007), accuracy 0.944 (SD 0.006), and macro F1 0.929 (SD 0.008). On the held-out test set (n = 247), macro AUC was 0.982 (95% CI: 0.965--0.995), accuracy 0.943, balanced accuracy 0.932, macro F1 0.927, and Cohen's kappa 0.909. SHAP analysis identified CDR Global as the dominant predictor for NC and MCI, while CDR-SB and MMSE together drove AD classification. Conclusion: An explainable machine learning model trained on routine clinical assessments achieves near-perfect three-class Alzheimer's detection. SHAP analysis reveals clinically plausible, class-specific feature importance patterns supporting clinical validity. Future work will extend this framework with speech biomarkers for multimodal detection.
Jul 2, 2026

Predicting Early Stages Of Alzheimer's Disease And Identifying Key Biomarkers Using Deep Artificial Neural Network And Ensemble Of Machine Learning Methodologies

Alzheimers disease (AD) is a brain disorder that develops slowly and mainly affects memory, thinking, language, and daily activities. It is one of the most common causes of dementia and creates many difficulties for patients as well as their families. In the early stage, the symptoms are often mild and may look like normal ageing. For this reason, many people are diagnosed late, when the disease has already progressed. At present, there is no complete cure for AD. Still, early detection can help doctors manage the condition better and take suitable steps at the right time. In this study, a machine learning model is proposed to detect the early stages of Alzheimers disease using clinical details, neuropsychological test scores, and neuroimaging-related measures. The data used in this work is collected from the Alzheimers Disease Neuroimaging Initiative (ADNI). As the dataset has missing values, iterative imputation is applied to fill them. The dataset also has class imbalance, which is handled using Borderline SVM-SMOTE. After that, feature selection is carried out using wrapper-based and embedded methods so that only important features are used for training. The selected features are divided into training and testing sets, and feature scaling is applied. A stacking ensemble model is developed using Logistic Regression, Extra Trees, Bagging KNN, and LightGBM as base classifiers. Along with this, an artificial neural network is also trained on the same dataset. The performance of these models is compared using precision, recall, F1-score, and AUC-ROC. This study aims to find the best classifier and also identify important biomarkers that may help in the early diagnosis of Alzheimers disease.
Sep 11, 2026

A Multimodal Explainable Deep Learning Framework for Alzheimer's Disease Diagnosis using 3D Magnetic Resonance Imaging and Clinical Data

Dementia is a major and growing global health burden, with Alzheimer's disease (AD) accounting for most cases. Timely and accurate diagnosis is central to managing this burden and increasingly depends on integrating complementary clinical and imaging information. Multimodal deep learning can combine these modalities for AD diagnosis, but how its explanations behave across modalities, fusion strategies, and cohorts remains unclear. We developed an explainable multimodal framework pairing a 3D CNN encoder for T1-weighted MRI with a feedforward network for harmonized clinical and demographic data, comparing varied model setups on three-way and pairwise diagnostic tasks using 6,479 internal records from the ADNI and 1,703 independent records from the OASIS-3. On ADNI, the tabular-only model achieved the highest three-class AUC-ROC of 0.879 and best discriminated cognitively normal (CN) versus mild cognitive impairment (MCI; 0.903), while cross-attention performed best for MCI versus AD (0.861); CN versus AD was highly discriminative overall. On OASIS-3, the vision-only model performed best (three-class AUC-ROC 0.910); CN versus MCI remained difficult, and no fusion strategy consistently outperformed single modalities across tasks and cohorts. SHAP and Integrated Gradients identified the MMSE as the dominant tabular feature in both cohorts, with global feature rankings agreeing strongly in ADNI (ρ=0.94ρ=0.94) and OASIS-3 (ρ=0.96ρ=0.96); CAM-based explanations, however, changed with model configuration and cohort. These findings show that multimodal performance and explanations are task, modality, fusion, and cohort-dependent: a dominant cognitive signal persisted across cohorts, but feature contributions and CAM explanations did not, underscoring the need to evaluate explainability under cohort shift rather than as a stable, intrinsic property.